Drug Discovery World feature article: ‘Target discovery and drug development – what comes after CRISPR?’

30th April 2020

Benedict Cross, Chief Technology Officer, discusses the changing landscape of drug discovery, and the potential of new multi-modal screening tools such as PROTEINi, the basis for PhoreMost’s SITESEEKER® platform.

For an area of research as important and impactful as drug discovery, it is surprising how often efforts are directed by short-term trends. We have seen an abundance in new tools and platforms over recent years, including hugely influential CRISPR-based technologies. How should these new technologies be used, to enable progression from target discovery to the clinic?

Read the full article in the Spring issue of DDW at: https://cld.bz/VZH1kT/6/


Media enquiries

Zyme Communications:
Katie Odgaard
katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947

At PhoreMost Ltd:
Dr Neil Torbett, CBO
neil.torbett@phoremost.com
Phone: +44 (0)1223 804 161